Search Materials

The Global Drug Facility (GDF) is a mechanism to expand access to, and availability of, high-quality anti-TB drugs and diagnostics to support the Stop TB Strategy. This document outlines progress that GDF has made to date, what still needs to be done and where high-level advocacy could help GDF to further scale up its activities.

Popularly known as “The Orange Guide”, the 6th edition of this small book provides practical guidance to health workers on the front line of TB control. It includes sections on HIV, MDR-TB and a review of the recommended treatment regimens.

In response to the urgent need to control the spread of TB, the U.S. Congress passed the Reauthorization Act supporting a substantial increase in USG funding for TB treatment and control over a five-year period. The Reauthorization Act requests the development of a USG Global Tuberculosis Strategy.

This report details the activities of the International Union Against Tuberculosis and Lung Disease (The Union) for the year 2008.

The aim of this handbook is to equip individuals and programs with the tools necessary for working with the media to spread messages regarding TB. The handbook walks the reader through the planning and execution of media outreach: from thinking about goals to attracting media attention. Tips and suggestions for developing key messages, handling interviews, writing news releases and calling journalists are also included...

This tool will assist countries and partners in conducting assessments of national tuberculosis (TB) programs to identify strengths and gaps related to preventing, diagnosing, and treating multidrug-resistant TB. It provides the starting point for planning for new activities to address drug-resistant TB...

This book is the first title in Wiley-Blackwell's new 'Infection Biology Series'. Early chapters focus on immunology and the problems facing vaccination strategies for both diseases. Later chapters deal with some of the most threatening consequences of this co-infection, such as the emergence of drug resistant TB.

Treatment Action Group (TAG) analyzes and reports on the annual funding of tuberculosis (TB ) research and development (R&D). The top 40 TB research funding institutions were surveyed for actual disbursements made for TB R&D in fiscal years 2005, 2006, and now 2007. The three-year data reveal trends in funding and demonstrates an alarming shortfall in the growth of TB R&D during the initial years covered by The Global Plan to Stop TB: 2006–2015.